EI
TVRD

EAM Investors’s Tvardi Therapeutics TVRD Stock Holding History

EAM Investors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,815
Closed -$1.85M – 327
2019
Q3 		$1.85M Buy
+2,815
New +$2.34M 0.49% 72
2018
Q4 		– Sell
-1,417
Closed -$1.22M – 330
2018
Q3 		$1.22M Buy
+1,417
New +$1.02M 0.18% 192
2017
Q3 		– Sell
-5,899
Closed -$3.27M – 355
2017
Q2 		$3.27M Sell
5,899
-347
-6% -$220K 0.54% 57
2017
Q1 		$4.13M Sell
6,246
-413
-6% -$221K 0.65% 19
2016
Q4 		$2.23M Buy
+6,659
New +$2.14M 0.3% 178
2016
Q1 		– Sell
-3,044
Closed -$1.85M – 352
2015
Q4 		$1.85M Buy
3,044
+1,501
+97% +$824K 0.24% 170
2015
Q3 		$794K Buy
+1,543
New +$1.03M 0.13% 278

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

EAM Investors's TVRD Position: Q4 2019 in Review

EAM Investors sold out of Tvardi Therapeutics (TVRD) in Q4 2019, closing a stake of 2,815 shares — an estimated $1.85M sold.

EAM Investors first reported a position in TVRD in Q3 2015 and held it in 7 quarters. The position peaked at $4.13M in Q1 2017. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • EAM Investors reported no remaining Tvardi Therapeutics position as of Q4 2019 after selling out during the quarter.
  • EAM Investors sold 2,815 Tvardi Therapeutics shares in Q4 2019, an estimated $1.85M.
  • EAM Investors first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 7 quarters.
  • EAM Investors's Tvardi Therapeutics position peaked at $4.13M in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on EAM Investors's 13F filing for Q4 2019, filed 11 Feb 2020.